Patents by Inventor Richard M Pastor

Richard M Pastor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS
    Publication number: 20230159555
    Abstract: Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
    Type: Application
    Filed: July 21, 2022
    Publication date: May 25, 2023
    Applicant: Genentech, Inc.
    Inventors: Paul GIBBONS, Kwong Wah LAI, Christian NILEWSKI, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Bing-Yan ZHU, Huifen CHEN
  • CYCLIC PEPTIDE ANTIBIOTICS
    Publication number: 20230025834
    Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
    Type: Application
    Filed: September 10, 2021
    Publication date: January 26, 2023
    Applicant: Genentech, Inc.
    Inventors: Guosheng WU, Emily J. HANAN, Marie-Gabrielle BRAUN, Sharada S. LABADIE, Keira GARLAND, Richard M. PASTOR, Paul Anthony GIBBONS, Yuhong FU, Yun-Xing CHENG
  • Sulfonylurea compounds as inhibitors of interleukin-1 activity
    Patent number: 11560391
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Grant
    Filed: January 15, 2021
    Date of Patent: January 24, 2023
    Assignee: Genentech, Inc.
    Inventors: Jeffrey A. Stafford, James M. Veal, Lynnie Lin Trzoss, Christopher McBride, Richard M. Pastor, Steven Thomas Staben, Craig Stivala, Matthew Volgraf
  • SULFONYLUREA COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210261568
    Abstract: The present disclosure relates to novel sulfonylurea compounds and related compounds useful in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Genentech, Inc.
    Inventors: Jeffrey A. STAFFORD, James M. VEAL, Lynnie Lin TRZOSS, Christopher MCBRIDE, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF
  • SULFONIMIDAMIDE COMPOUNDS AS INHIBITORS OF INTERLEUKIN-1 ACTIVITY
    Publication number: 20210253596
    Abstract: The present disclosure relates to novel sulfonimidamide compounds and related compounds and their use in treating a disorder responsive to modulation of cytokines such as IL-1? and IL-18, modulation of NLRP3 or inhibition of the activation of NLRP3 or related components of the inflammatory process.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Christopher MCBRIDE, Lynnie Lin TRZOSS, Amogh BOLOOR, Nadezda V. SOKOLOVA, Richard M. PASTOR, Steven Thomas STABEN, Craig STIVALA, Matthew VOLGRAF, Sarah M. BRONNER
  • Integrase inhibitors
    Patent number: 8008287
    Abstract: Tricyclic compounds, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
    Type: Grant
    Filed: May 16, 2007
    Date of Patent: August 30, 2011
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Salman Y. Jabri, Haolun Jin, Rachael A. Lansdown, Samuel E. Metobo, Michael R. Mish, Richard M. Pastor
  • INTEGRASE INHIBITORS
    Publication number: 20090306054
    Abstract: Tricyclic compounds of formulae I-III, protected intermediates thereof, and methods for inhibition of HIV-integrase are disclosed.
    Type: Application
    Filed: May 16, 2007
    Publication date: December 10, 2009
    Applicant: Gilead Sciences ,Inc.
    Inventors: Zhenhong R. Cai, Salman Y. Jabri, Haolun Jin, Rachel A. Lansdown, Samuel E. Metobo, Michael R. Mish, Richard M. Pastor
  • Antiviral compounds
    Publication number: 20080076740
    Abstract: The invention is related to phosphorus substituted anti-viral inhibitory compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
    Type: Application
    Filed: July 27, 2006
    Publication date: March 27, 2008
    Inventors: Zhenhong R. Cai, Salman Y. Jabri, Haolun Jin, Choung U. Kim, Samuel E. Metobo, Michael R. Mish, Richard M. Pastor
  • Amidine inhibitors of serine proteases
    Patent number: 6838479
    Abstract: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: January 4, 2005
    Assignee: Genentech, Inc.
    Inventors: Richard M Pastor, Dean R. Artis, Alan G. Olivero
  • Amidine inhibitors of serine proteases
    Publication number: 20030229133
    Abstract: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
    Type: Application
    Filed: March 4, 2003
    Publication date: December 11, 2003
    Inventors: Richard M. Pastor, Dean R. Artis, Alan G. Olivero
  • Amidine inhibitors of serine proteases
    Patent number: 6410733
    Abstract: Inhibitors of serine proteases are provided having formula (I) wherein X, R1, R2, R3, R4 and R5 are as defined herein. In particular, the compounds bind to factor VIIa, tissue factor/factor Xa complex, thrombin, trypsin, plasmin and kallikrein and have anticoagulant activity. Pharmaceutical compositions comprising the compounds are useful for inhibiting the formation of veinous and/or arterial thrombi in vivo.
    Type: Grant
    Filed: September 5, 2001
    Date of Patent: June 25, 2002
    Assignee: Genentech, Inc.
    Inventors: Richard M. Pastor, Dean R. Artis, Alan G. Olivero
  • AMIDINE INHIBITORS OF SERINE PROTEASES
    Publication number: 20020055469
    Abstract: Inhibitors of serine proteases are provided having formula (I) 1
    Type: Application
    Filed: September 5, 2001
    Publication date: May 9, 2002
    Applicant: GENENTECH, INC.
    Inventors: Richard M. Pastor, Dean R. Artis, Alan G. Olivero